Versor Investments LP Takes Position in USANA Health Sciences, Inc. $USNA

Key Points

• Versor Investments LP acquired a new stake in USANA Health Sciences, buying 13,000 shares valued at approximately $351,000, which represents about 0.07% ownership in the company.
• Several major institutional investors have increased their holdings in USANA, with notable purchases from Wells Fargo, Invesco, and Barclays, reflecting a growing interest in the company.
• USANA's stock price has shown volatility, with a 1-year low of $23.10 and a high of $41.83; it recently opened at $30.61, and the company reported better-than-expected earnings.

Versor Investments LP bought a new position in shares of USANA Health Sciences, Inc. (NYSE:USNA - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 13,000 shares of the company's stock, valued at approximately $351,000. Versor Investments LP owned 0.07% of USANA Health Sciences at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. American Century Companies Inc. increased its position in USANA Health Sciences by 9.2% during the first quarter. American Century Companies Inc. now owns 255,242 shares of the company's stock worth $6,884,000 after acquiring an additional 21,445 shares during the period. Russell Investments Group Ltd. increased its holdings in USANA Health Sciences by 48.8% in the 1st quarter. Russell Investments Group Ltd. now owns 10,179 shares of the company's stock valued at $275,000 after buying an additional 3,337 shares during the period. Public Sector Pension Investment Board increased its holdings in USANA Health Sciences by 26.8% in the 1st quarter. Public Sector Pension Investment Board now owns 35,063 shares of the company's stock valued at $946,000 after buying an additional 7,403 shares during the period. Nuveen LLC bought a new stake in USANA Health Sciences in the 1st quarter valued at $895,000. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new stake in USANA Health Sciences in the 1st quarter valued at $870,000. Institutional investors own 54.25% of the company's stock.

Insider Transactions at USANA Health Sciences

In other USANA Health Sciences news, Director Gilbert A. Fuller sold 1,058 shares of the company's stock in a transaction dated Thursday, August 7th. The shares were sold at an average price of $29.10, for a total transaction of $30,787.80. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider David Mulham Mulham sold 3,515 shares of the company's stock in a transaction dated Wednesday, July 30th. The shares were sold at an average price of $30.26, for a total transaction of $106,363.90. Following the transaction, the insider owned 9,260 shares in the company, valued at approximately $280,207.60. The trade was a 27.51% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 5,073 shares of company stock worth $151,982. Corporate insiders own 0.63% of the company's stock.

USANA Health Sciences Stock Performance

Shares of NYSE:USNA traded up $0.41 on Wednesday, hitting $32.11. The stock had a trading volume of 76,709 shares, compared to its average volume of 107,625. USANA Health Sciences, Inc. has a twelve month low of $23.10 and a twelve month high of $41.83. The firm's 50 day moving average price is $31.09 and its 200-day moving average price is $29.57. The company has a market capitalization of $586.61 million, a price-to-earnings ratio of 17.84, a price-to-earnings-growth ratio of 1.01 and a beta of 0.61.

USANA Health Sciences (NYSE:USNA - Get Free Report) last issued its earnings results on Tuesday, July 22nd. The company reported $0.74 EPS for the quarter, beating the consensus estimate of $0.54 by $0.20. The company had revenue of $235.85 million for the quarter, compared to the consensus estimate of $225.20 million. USANA Health Sciences had a net margin of 3.79% and a return on equity of 9.48%. USANA Health Sciences has set its FY 2025 guidance at 2.350-3.000 EPS. As a group, sell-side analysts predict that USANA Health Sciences, Inc. will post 2.45 EPS for the current year.

Analysts Set New Price Targets

Separately, Wall Street Zen raised shares of USANA Health Sciences from a "hold" rating to a "buy" rating in a report on Thursday, May 22nd. Two analysts have rated the stock with a Hold rating, According to MarketBeat, USANA Health Sciences currently has a consensus rating of "Hold" and a consensus price target of $36.00.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.